colorectal cancer
Conditions
Interventions
Azilsartan Oral administration once a day(max 6 month)
Amlodipine Oral administration once a day(max 6 month)
Sponsors
Iwate Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with colon cancer by histology or cytology 2) Patients who had metastasis / recurrence in the image confirmed 3) Patients who are receiving bevacizumab 4) Patients diagnosed with hypertension after bevacizumab administration 5) Patients scheduled to be treated by ARB or CCB 6) Patients with ECOG PS 0 to 2 7) Patients of age 20 years or older 8) Scheduled research subjects who received the notification Patients who received written consent from participants to participate in this study
Exclusion criteria
Exclusion criteria: 1) Patients who have continued therapy with bevacizumab for more than 3 months 2) Patients who show proteinuria at least once within 4 weeks before consent acquisition 3) Patients with renal dysfunction of eGFR less than 30 mL / min / 1.73 m 2 at the time of consent acquisition 4) Patients who have taken the following medications before consent acquisition: ARB, angiotensin II converting enzyme inhibitor, direct renin inhibitor, diuretic, CCB, alpha / beta antagonist 5) Patients with diabetes 6) Patients with cardiovascular disorders 7) Patients who may be pregnant or pregnant 8) Patients who are considered difficult to register in this study due to clinically problematic mental illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of decrease in proteinuria | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of decrease in systolic / diastolic blood pressure Biochemical examination (TP, Alb, AST, ALT, BUN, SCr, T-Bil, Na, K, Cl, Ca) Urinalysis (uTP, uAlb, uCr, uNa, urinary osmotic pressure) Serum and urinary ET-1, AT-2, VEGF-A Adverse event related antihypertensive | — |
Countries
Japan
Contacts
Public ContactSatoru Nihei
Iwate Medical University Faculty of clinical pharmacy course
Outcome results
None listed